Pharmacological βAR agonists indeed acutely stimulate post-synaptic receptors on cancer cells or host cells, in contrast to endogenous nerve-released NE following SNS activation via chronic stress or other means, which is buffered by homeostatic mechanisms aimed at controlling excess SNS activation. The gene discussed is ADRB2; the disease is cancer.